Other therapeutic strategies (TK inhibitors and monoclonal antibodies) targeting HGF/c-MET signalling pathways are currently under evaluation in metastatic BC, especially in BL or TNBC settings. This evidence concerns the gene TKT and Burkitt lymphoma.